From Friday's PR: "Generex Biotechnology (www.gene

From Friday's PR: "Generex Biotechnology (www.generex.com) (OTCQB:GNBT) today announced that the Company has identified a public, development stage company that is fully reporting and current on its filings with the SEC, and DTC eligible that will serve as a vehicle for the spin-out of its subsidiary NuGenerex Immuno-Oncology (NGIO) as a separate public company. Generex is in final negotiations to retain the controlling interest of the outstanding shares of the acquisition target and expects to complete the contracts and file a super 8K in the coming weeks. Generex and its shareholders who have received the 1:4 NGIO dividend will initially hold 100% of the NGIO shares following the acquisition, which will set the stage for the subsequent planned merger with Kiromic."

This is new to me. I always thought the merger would happen before the spinout. It will be interesting because we will get to see how the market values Antigen Express and then later how the market will adjust that valuation after Kiromic is added.

It also is a real world example of how the 21 million shares being returned to the treasury, post split, will be used- to acquire income producing assets.

These next 2 weeks are going to be very interesting. I'm dusted off and ready to roll.